| 영문 | multiple myeloma | 한글 | 다발골수종 |
|---|---|---|---|
| 설명 | 다발성 원발성골종양. 머리뼈-갈비뼈-복장뼈-척추뼈-골반 등에 잘 나타나고, 물렁물렁한 종괴를 형성하며, 뼈의 흡수가 일어나고, 40~60세 남자에게 많이 발생한다. 골수종 종양세포는 형질세포에서 유래한 것이어서 형질세포종이라고도 한다. 과거에는 형질세포성골수종 이외에는 다른 골수조혈요소에서 생기는 골수종이라고 생각했지만 현재는 부정되고 있다. 형질세포는 원래 면역글로불린을 생산하는 세포이며, 그것이 종양화한 다발 골수종 환자에서도 대부분 혈청 속에 면역 글로불린이 증가된 것을 볼 수 있다. 증가한 글로불린은 IgG나 IgA인 경우가 많지만 다른 형도 있다. 골수종 환자 약 50%는 오줌에서 벤스죤스단백질이 검출되는데, 이 단백질의 축적에 의해 요세관이 파괴되고, 콩팥경화가 일어난다. 골수종 환자에서는 혈청단백 이상으로 가끔 아밀로이드증이 나타난다. 뼈 X선 소견으로서는 도려낸 병터, 골융해상, 병적골절이 관찰된다. |
||
| 영문 | protein | 한글 | 단백질 |
|---|---|---|---|
| 설명 | 탄소, 수소, 산소, 질소, 황을 함유하고 있는 유기화합물로, 모든 세포의 원형질을 이루고 있는 기본 구성물질이다. 단백질은 그 단위인 아미노산들이 펩티드결합에 의해 결합되어 있으며, 보통 20개의 아미노산들이 다른 순서와 조성을 가지고 배열되어, 독특한 하나의 단백질을 형성하게 된다. |
||
| B-J protein | Bence-Jones Protein 의의; Multiple Myeloma |
|---|---|
| PC-BMP | phosphorylcholine-m-binding myeloma protein |
| MM | Multiple Myeloma |
| MM | macromolecule; Maelzels metronome; major medical [insurance]; malignant melanoma; manubrium to malle... |
| SMM | smoldering multiple myeloma |
| M.M. | Multiple Myeloma |
|---|---|
| MM | Myeloma |
| SMM | Smoldering multiple myeloma |
| HMCL | human myeloma cell line |
| G protein | 5'-triphosphate-binding protein |
| myeloma protein | <haematology, oncology> The immunoglobulins and Bence Jones proteins secreted by myeloma cells. (18 Nov 1997) |
|---|---|
| amyloidosis of multiple myeloma | Foci of amyloidosis in mesenchymal tissues of some persons with multiple myeloma; no direct relation between amyloid and Bence Jones protein is conclusively known. (05 Mar 2000) |
| cancer, multiple myeloma | A bone marrow cancer involving a type of white blood cell called a plasma (or myeloma) cell. The tumour cells can form a single collection (a plasmacytoma) or many tumours (multiple myeloma). Plasma cells are part of the immune system and make antibodies. Because patients have an excess of identical plasma cells, they have too much of one type of antibody. As myeloma cells increase in number, they damage and weaken the bones, causing pain and often fractures. When bones are damaged, calcium is released into the blood leading to hypercalcaemia (excess calcium in the blood) and that causes loss of appetite, nausea, thirst, fatigue, muscle weakness, restlessness, and confusion. Myeloma cells prevent the bone marrow from forming normal plasma cells and other white blood cells important to the immune system so patients may not be able to fight infections. The cancer cells can also prevent the growth of new red blood cells, causing anaemia. Excess antibody proteins and calcium may prevent the kidneys from filtering and cleaning the blood properly Cancer, non-Hodgkin's lymphoma: A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy. (12 Dec 1998) |
| cancer, myeloma | A bone marrow cancer involving a type of white blood cell called a plasma (or myeloma) cell. The tumour cells can form a single collection (a plasmacytoma) or many tumours (multiple myeloma). Plasma cells are part of the immune system and make antibodies. Because patients have an excess of identical plasma cells, they have too much of one type of antibody. As myeloma cells increase in number, they damage and weaken the bones, causing pain and often fractures. When bones are damaged, calcium is released into the blood leading to hypercalcaemia (too much calcium in the blood) and that causes loss of appetite, nausea, thirst, fatigue, muscle weakness, restlessness, and confusion. Myeloma cells prevent the bone marrow from forming normal plasma cells and other white blood cells important to the immune system so patients may not be able to fight infections. The cancer cells can also prevent the growth of new red blood cells, causing anaemia. Excess antibody proteins and calcium may prevent the kidneys from filtering and cleaning the blood properly. (12 Dec 1998) |
| giant cell myeloma | A bone tumour composed of cellular spindle-cell stroma containing scattered multinucleated giant cells resembling osteoclasts. The tumours range from benign to frankly malignant lesions. The tumour occurs most frequently in an end of a long tubular bone in young adults. (12 Dec 1998) |
| plasma cell myeloma | Cells resemble mature or immature plasma cells with nuclei that appear cleaved or resemble immunoblasts. The tumour cells are CD19- , CD20- , CD22- and SIg- , but are also cIg+ and CD38+. The Ig heavy and light chain genes can be translocated or deleted. These neoplasms are often disseminated BM tumours of adults and progress to multiple myeloma. (05 Mar 2000) |
| multiple myeloma | <oncology, tumour> See myeloma cell. (18 Nov 1997) |
| myeloma | <oncology, tumour> A malignant tumour composed of plasma cells of the type normally found in the bone marrow. (18 Nov 1997) |
| myeloma cell | <haematology, oncology> Neoplastic plasma cell. The proliferating plasma cells often replace all the others within the marrow, leading to immune deficiency and frequently there is destruction of the bone cortex. Because they are monoclonal in origin they secrete a monoclonal immunoglobulin. Bence Jones proteins are monoclonal immunoglobulin light chains overproduced by myeloma cells and excreted in the urine. Myeloma cell lines are used for producing hybridomas in raising monoclonal antibodies. (18 Nov 1997) |
| endothelial myeloma | A malignant primary bone tumour that arises most commonly in the first three decades of life. It is highly malignant (prone to spread) and often requires treatment with some combination of radiation therapy and chemotherapy. (27 Sep 1997) |
| L-chain myeloma | bence Jones myeloma |
| acetoacetyl-acyl carrier protein synthase | <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin Registry number: EC 2.3.1.- Synonym: acetoacetyl-acp synthase (26 Jun 1999) |
| acid soluble spore protein | <molecular biology> A DNA binding protein in the spores of some bacteria, thought to stabilise the DNA in an A configuration, so protecting it from cleavage by enzymes or UV light. (18 Nov 1997) |
| acute-phase protein | <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor). Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold. Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability. These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers. See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity. (25 Jun 1999) |
| acyl-(acyl-carrier-protein)-phospholipid acyltransferase | <enzyme> Catalyses the formation of phosphatidylethanolamine from acyl-acyl carrier protein and 2-acyl-sn-glycero-3-phosphoethanolamine Registry number: EC 2.3.1.40 Synonym: 2-acyl-gpe acyltransferase, 2-acylglycerophosphoethanolamine acyltransferase (26 Jun 1999) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|